Objective
To determine whether cannabis use is associated with a change in the risk of incident nonmedical prescription opioid use and opioid use disorder at 3 year follow-up.
Methods
We used logistic regression models to assess prospective associations between cannabis use at Wave 1 (2001–2002) and nonmedical opioid use and prescription opioid use disorder at Wave 2 (2004–2005) of the National Epidemiologic Survey on Alcohol and Related Conditions. Corresponding analyses were performed among adults with moderate or more severe pain and with nonmedical opioid use at Wave 1. Cannabis and prescription opioid use were measured with a structured interview (AUDADIS-IV). Other covariates included age, sex, race/ethnicity, anxiety or mood disorders, family history of drug, alcohol, and behavioral problems, and in opioid use disorder analyses, nonmedical opioid use.
Results
In logistic regression models, Wave 1 cannabis use was associated with increased incident non-medical prescription opioid use (OR=5.78, 95%CI=4.23–7.90) and opioid use disorder (OR=7.76, 95%CI=4.95–12.16) at Wave 2. These associations remained significant following adjustment for background characteristics (non-medical opioid use: AOR=2.26, 95%CI=1.86–3.69; opioid use disorder: AOR=2.18, 95%CI=1.14–4.14). Among adults with pain at Wave 1, cannabis use was also associated with increased incident non-medical opioid use (AOR=2.99, 95%CI=1.63–5.47) and approached significance with incident prescription opioid use disorder (AOR=2.14, 95%CI=0.95–4.83). Among adults with nonmedical opioid use at Wave 1, cannabis use was also associated with an increase in non-medical opioid use (AOR=3.13, 95%CI=1.19–8.23).
Conclusions
Cannabis use appears to increase rather than decrease the risk of developing nonmedical prescription opioid use and opioid use disorder.